Login / Signup

New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents.

Laurent Roberto ChiarelliMatteo MoriGiangiacomo BerettaArianna GelainElena PiniJose Camilla SammartinoGiovanni StelitanoDaniela BarloccoLuca CostantinoMargherita LapilloGiulio PoliIsabella CaligiuriFlavio RizzolioMarco BellinzoniTiziano TuccinardiStefania VillaFiorella Meneghetti
Published in: Journal of enzyme inhibition and medicinal chemistry (2019)
Starting from the analysis of the hypothetical binding mode of our previous furan-based hit (I), we successfully achieved our objective to replace the nitro moiety, leading to the disclosure of a new lead exhibiting a strong activity against MbtI. Our best candidate 1 h displayed a Ki of 8.8 µM and its antimycobacterial activity (MIC99 = 250 µM) is conceivably related to mycobactin biosynthesis inhibition. These results support the hypothesis that 5-phenylfuran-2-carboxylic derivatives are a promising class of MbtI inhibitors.
Keyphrases
  • neoadjuvant chemotherapy
  • risk assessment
  • binding protein
  • cell wall